

BIOLIFE SOLUTIONS INC  
Form 8-K  
March 14, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 14, 2019**

**BIOLIFE SOLUTIONS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation)

**001-36362**

(Commission File Number)

**94-3076866**

(IRS Employer Identification No.)

**3303 Monte Villa Parkway,**

**Bothell, WA 98021**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (425) 402-1400

N/A

Edgar Filing: BIOLIFE SOLUTIONS INC - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02 Results of Operations and Financial Condition.**

On March 14, 2019, BioLife Solutions, Inc. (the “Company”) issued a press release announcing the financial results and operational highlights for the fourth quarter and full year ended December 31, 2018. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

**Item 8.01 Other Events.**

On March 14, 2019, the Company issued a press release announcing that the Company entered into an agreement to acquire Astero Bio Corporation, a privately-held company in the design, development and commercialization of novel automated thawing devices. A copy of the press release is furnished as Exhibit 99.2 to this current report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

| <b>Exhibit No.</b> | <b>Description</b>  |
|--------------------|---|
| 99.1               | <u>Press release, dated March 14, 2019 (Financial Results and Operational Highlights)</u> |
| 99.2               | <u>Press release, dated March 14, 2019 (Announcement of Acquisition)</u>                  |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Biolife Solutions, Inc.**

Date: March 14, 2019 By: /s/ Roderick de Greef  
Name: Roderick de Greef

Title: Chief Financial Officer